A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

NCT ID: NCT01820572

Last Updated: 2021-01-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

446 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-27

Study Completion Date

2019-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Belatacept

Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months

Group Type EXPERIMENTAL

Belatacept

Intervention Type DRUG

CNI

Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months

Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months

Group Type ACTIVE_COMPARATOR

Tacrolimus

Intervention Type DRUG

Cyclosporine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Belatacept

Intervention Type DRUG

Tacrolimus

Intervention Type DRUG

Cyclosporine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMS 224818 Nulojix®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, ages 18-75 inclusive
* Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment
* Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) \[Cyclosporine A (CsA) or Tacrolimus (TAC)\] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids
* Stable renal function for 12 weeks prior to enrollment without new onset proteinuria
* Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 \[Modification of Diet in Renal Disease study (MDRD) 4-formula\]

Exclusion Criteria

* Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown
* History of acute rejection (AR) within 3 months prior to enrollment
* History of antibody mediated rejection
* Positive T-cell lymphocytotoxic cross match
* Proteinuria \>1 g/day or \>0.5 g/day if diabetic
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UAB Division of Nephrology

Birmingham, Alabama, United States

Site Status

Mayo Clinic Hospital

Phoenix, Arizona, United States

Site Status

Loma Linda University Medical Center (LLUMC) - Children's Hospital - Transplantation Institute

Loma Linda, California, United States

Site Status

UCLA Kidney Transplant Research Office

Los Angeles, California, United States

Site Status

Keck Medical Center of USC (PI Address)

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Transplant Research Institute (PI Address)

Los Angeles, California, United States

Site Status

University of California, San Francisco (UCSF)-Kidney Transplant Service

Sacramento, California, United States

Site Status

California Institute Of Renal Research

San Diego, California, United States

Site Status

California Pacific Medical Center, Depart of Transplantation (PI Address)

San Francisco, California, United States

Site Status

UCSF Medical Center

San Francisco, California, United States

Site Status

University of Colorado Denver (PI Address)

Aurora, Colorado, United States

Site Status

Denver Nephrologists, PC

Denver, Colorado, United States

Site Status

Yale Medical Group

New Haven, Connecticut, United States

Site Status

Florida Hospital Transplant Institute (PI Address)

Orlando, Florida, United States

Site Status

Central Pharmacy

St. Petersburg, Florida, United States

Site Status

Tampa General Medicine Group

Tampa, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Medical College of Georgia at Augusta University

Augusta, Georgia, United States

Site Status

RUSH University Transplant Program (PI Address)

Chicago, Illinois, United States

Site Status

University of Wisconsin School of Medicine and Public Health (PI Address)

Chicago, Illinois, United States

Site Status

University of Iowa Health Care (PI Address)

Iowa City, Iowa, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Maine Transplant Program

Portland, Maine, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Henry Ford's Transplant Institute

Detroit, Michigan, United States

Site Status

St. Clair Nephrology Research

Roseville, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Washington Univ School of Med

St Louis, Missouri, United States

Site Status

University or Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Saint Barnabas Medical Center

Livingston, New Jersey, United States

Site Status

University of Buffalo

Buffalo, New York, United States

Site Status

Recanati/Miller Transplantation Institue (PI Address)

New York, New York, United States

Site Status

Carolinas Medical Center (PI Address)

Charlotte, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

East Carolina Univ Nephrology Clin Res. Lab

Greenville, North Carolina, United States

Site Status

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Central PA Transplant Foundation

Harrisburg, Pennsylvania, United States

Site Status

Drexel University College of Medicine

Philadelphia, Pennsylvania, United States

Site Status

Penn Medicine

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina, SCTR Research Nexus

Charleston, South Carolina, United States

Site Status

Methodist University Hospital Transplant Institute (PI Address)

Memphis, Tennessee, United States

Site Status

Vanderbilt University Medical Center- GI Research Office

Nashville, Tennessee, United States

Site Status

Baylor University Medical Center

Dallas, Texas, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Baylor All Saints Medical Center at Ft. Worth

Fort Worth, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Memorial Hermann - Texas Medical Center (Tmc), The University Of Texas Medical School At Houston

Houston, Texas, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

University of Utah Depart of Nephrology (PI Address)

Salt Lake City, Utah, United States

Site Status

University of Virginia Health System (PI Address)

Charlottesville, Virginia, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States

Site Status

Swedish Medical Center-Swedish Organ Transplant and Liver Center

Seattle, Washington, United States

Site Status

University of Washington Medical Center (PI Address & Study Supplies Address)

Seattle, Washington, United States

Site Status

Providence Sacred Heart Medical Center and Childrens Hospital

Spokane, Washington, United States

Site Status

Medical College of WI Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

Local Institution

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Mendoza, Buenos Aires, Argentina

Site Status

Local Institution

Cardoba, Córdoba Province, Argentina

Site Status

Local Institution

Rosario, Santa Fe Province, Argentina

Site Status

Local Institution

Buenos Aires, , Argentina

Site Status

Local Institution

CABA, , Argentina

Site Status

Local Institution

Córdoba, , Argentina

Site Status

Local Institution

Santa Fe, , Argentina

Site Status

Local Institution

Feldkirch, , Austria

Site Status

Local Institution

Graz, , Austria

Site Status

Local Institution

Innsbruck, , Austria

Site Status

Local Institution

Linz, , Austria

Site Status

Local Institution

Vienna, , Austria

Site Status

Local Institution

Cali, Valle del Cauca Department, Colombia

Site Status

Local Institution

Bogotá, , Colombia

Site Status

Local Institution

Paris, Cedex 15, France

Site Status

Local Institution

Bois-Guillaume, , France

Site Status

Local Institution

Bordeaux, , France

Site Status

Local Institution

Brest, , France

Site Status

Local Institution

Créteil, , France

Site Status

Local Institution

Grenoble, , France

Site Status

Local Institution

Le Kremilin Bicretre, , France

Site Status

Local Institution

Lyon, , France

Site Status

Local Institution

Paris, , France

Site Status

Local Institution

Strasbourg, , France

Site Status

CHU Rangueil

Toulouse, , France

Site Status

Local Institution

Berlin, , Germany

Site Status

Local Institution

Dresden, , Germany

Site Status

Local Institution

Erlangen, , Germany

Site Status

Local Institution

Essen, , Germany

Site Status

Local Institution

Frankfurt am Main, , Germany

Site Status

Local Institution

Hamburg, , Germany

Site Status

Local Institution

Hanover, , Germany

Site Status

Local Institution

Heidelberg, , Germany

Site Status

Local Institution

Kiel, , Germany

Site Status

Local Institution

Lübeck, , Germany

Site Status

Local Institution

Mannheim, , Germany

Site Status

Local Institution

München, , Germany

Site Status

Local Institution

Münster, , Germany

Site Status

Local Institution

Regensburg, , Germany

Site Status

Local Institution

Würzburg, , Germany

Site Status

Local Institution

Amsterdam, , Netherlands

Site Status

Local Institution

Amsterdam, , Netherlands

Site Status

Local Institution

Groningen, , Netherlands

Site Status

Local Institution

Leiden, , Netherlands

Site Status

Local Institution

Nijmegen, , Netherlands

Site Status

Local Institution

Utrecht, , Netherlands

Site Status

Local Institution

Oslo, , Norway

Site Status

Local Institution

Toensberg Norge, , Norway

Site Status

Local Institution

Gothenburg, , Sweden

Site Status

Local Institution

Stockholm, , Sweden

Site Status

Local Institution

Uppsala, , Sweden

Site Status

Local Institution

Bern, , Switzerland

Site Status

Local Institution

Geneva, , Switzerland

Site Status

Local Institution

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Austria Colombia France Germany Netherlands Norway Sweden Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, de Fijter JW, Rostaing L, Berger SP, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628. Epub 2021 Dec 1.

Reference Type DERIVED
PMID: 34706967 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-001314-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IM103-116

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bela 8 Week Dosing
NCT02560558 COMPLETED PHASE4